GLP-1 Vision Loss (NAION) Lawsuit 2026: Semaglutide Eye Claims

Semaglutide drugs sold as Ozempic, Wegovy, and Rybelsus are the subject of product liability claims alleging they caused a serious eye condition called NAION, a sudden and usually permanent loss of vision. These claims are centralized in a federal multidistrict litigation that is separate from the better known stomach injury cases, and the underlying science is recent and still being studied. This page explains the claims, the science, and the current status neutrally. It is general information and attorney advertising, not legal advice, and not a statement that anyone has a claim.

This page is part of our Mass Tort & Product Liability overview, and it concerns a different injury from our Ozempic and GLP-1 stomach injury guide.

What NAION is and the alleged harm

Non-arteritic anterior ischemic optic neuropathy, or NAION, is a condition in which blood flow to the front of the optic nerve is interrupted, causing sudden vision loss in one eye that is usually painless and often permanent. There is no proven treatment that reverses it, and a minority of patients later experience the second eye becoming involved. NAION is the most common sudden optic nerve disorder in adults over 50, and it has its own independent risk factors, including diabetes, high blood pressure, sleep apnea, and a particular optic nerve shape sometimes called a crowded disc. The lawsuits allege that semaglutide increases the risk of NAION and that the manufacturer did not adequately warn patients and prescribers. These are descriptions of the allegations, not a finding that semaglutide caused any individual person's vision loss.

Note: These are allegations being tested in court. NAION has several recognized causes unrelated to any medication, and a defendant can be expected to argue that another factor explains a given case. A lawsuit reflects what a plaintiff claims, not a final determination of liability.

What the science and regulators say

The evidence linking semaglutide to NAION is recent and not uniform. In July 2024, researchers at Mass Eye and Ear, a Harvard affiliated hospital, published a study in JAMA Ophthalmology reporting that patients prescribed semaglutide had a higher rate of NAION than comparable patients, with a hazard ratio of about 4 among people with type 2 diabetes and higher among people who were overweight or obese. The authors were explicit that the study suggested an association and that further research was needed to assess causation. Later and larger population studies found a real but smaller association: a 2025 Danish and Norwegian registry study reported roughly a threefold relative increase, and a large Danish cohort found that semaglutide roughly doubled the five year risk, while both stressed that the absolute risk remains low.

Regulators have described the risk as very rare. In 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide, occurring in up to about 1 in 10,000 users, and recommended adding it to product information, and the World Health Organization issued an alert to clinicians. In February 2026, the UK medicines regulator advised that semaglutide may very rarely be associated with NAION and that product information would be updated. As of mid 2026, the U.S. Food and Drug Administration had not added a NAION warning to the U.S. prescribing information for these drugs. The presence, or absence, of a warning reflects a regulator's assessment of reports and studies, not proof that the drug caused any particular case.

Note: Nothing here establishes that semaglutide causes NAION or that it caused any individual's vision loss. The studies disagree on the size of the risk, the absolute risk appears low, and the science continues to evolve.

A separate litigation from the GLP-1 stomach injury cases

It is important not to confuse this litigation with the larger GLP-1 stomach injury cases. The vision claims are handled in MDL No. 3163, while the gastrointestinal claims, which allege injuries such as gastroparesis and intestinal obstruction, are handled in MDL No. 3094. Both are centralized in the Eastern District of Pennsylvania before Judge Karen S. Marston, but they are separate proceedings with separate dockets, different injuries, different medical experts, and different proof of causation. The panel created a distinct MDL for the eye claims specifically so the vision science would be developed on its own. Our companion guide covers the stomach injury litigation in detail.

The status of the NAION litigation (as of June 2026)

The Judicial Panel on Multidistrict Litigation created MDL No. 3163, formally titled In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation, by a transfer order entered on December 15, 2025, consolidating an initial group of cases in the Eastern District of Pennsylvania before Judge Karen S. Marston. As of June 2026 it remains a much smaller docket than the gastrointestinal MDL, on the order of several dozen cases, and it is in early pretrial coordination. There have been no bellwether trials, no verdicts, and no settlement, and the central question of whether the science supports a causal link has not been decided. Litigation status can change quickly, so the current posture should be confirmed before relying on any figure.

Who may be involved

The people generally involved in this litigation are individuals who were prescribed and took a semaglutide product, such as Ozempic, Wegovy, or Rybelsus, and were later diagnosed with NAION or sudden, unexplained vision loss in one eye. Whether any particular person may have a claim depends on the specific facts, including which drug was used and for how long, the timing and diagnosis of the vision loss, the medical records, and the law of the relevant state. Because NAION has several independent causes, a key question in any case is whether the evidence connects the vision loss to the drug rather than to another risk factor. Use of one of these drugs alone does not establish a claim, and nothing here suggests that every patient has a claim or that any outcome is assured.

Deadlines and why they matter

Claims like these are subject to statutes of limitations, which are legal deadlines to file suit. These deadlines vary by state and by the type of claim, and many states measure the deadline from when a person knew or reasonably should have known that an injury may be linked to a product, a concept sometimes called the discovery rule. Because the studies and regulatory actions described above are recent, the question of when a person reasonably should have made that connection can be contested. There is no single national deadline, and this page does not state any individual's deadline. Missing a deadline can permanently bar a claim, so people who believe they may be affected often act promptly, and a licensed attorney in the relevant state can determine which deadline applies.

How to evaluate your options

If you are trying to understand your legal options, the appropriate step is to speak with a licensed attorney who handles this type of case. An attorney can assess the facts, explain the law in your state, and advise whether you may have a claim, which this page cannot do. It helps to gather any records you have, such as proof of which semaglutide product you used and when, your prescription and pharmacy history, and the ophthalmology records confirming an NAION diagnosis and its date. Most mass tort and personal injury attorneys offer a free, confidential consultation, and many work on a contingency basis, meaning a fee is generally owed only if there is a recovery. A consultation creates no obligation.